Revolution Medicines

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2015-01-01

Employees: 378

Market Cap: $7.2B

Website: http://www.revmed.com

Introduction: Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Clinical Trials

Study of Daraxonrasib (RMC-6236) in Previously Treated Patients With RAS Mutated NSCLC (RASolve 301)

Phase 3

Recruiting

Conditions: NSCLC (Non-small Cell Lung Cancer)
Non-Small Cell Lung Cancer
NSCLC
NSCLC (Non-small Cell Lung Carcinoma)
NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions: Drug: daraxonrasib
Drug: docetaxel

First Posted Date: 2025-03-18

Last Posted Date: 2025-05-21

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 420

Registration Number: NCT06881784

Locations: 🇺🇸
SCRI Oncology Partners - Tennessee, Nashville, Tennessee, United States
🇺🇸
Taylor Cancer Research Center, Maumee, Ohio, United States
🇺🇸
Utah Cancer Specialists, Salt Lake City, Utah, United States

and more 2 locations

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Phase 3

Recruiting

Conditions: Pancreatic Cancer
PDAC
PDAC - Pancreatic Ductal Adenocarcinoma

Interventions: Drug: RMC-6236
Drug: Gemcitabine
Drug: nab-paclitaxel
Drug: Irinotecan
Drug: Liposomal irinotecan
Drug: 5-fluorouracil
Drug: leucovorin
Drug: Oxaliplatin

First Posted Date: 2024-10-03

Last Posted Date: 2025-05-21

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 460

Registration Number: NCT06625320

Locations: 🇪🇸
Hospital 12 de Octubre, Madrid, Spain
🇺🇸
City of Hope-Duarte, Duarte, California, United States
🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 44 locations

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

Phase 1

Recruiting

Conditions: PDAC
CRC
Pancreatic Ductal Adenocarcinoma
Metastatic Pancreatic Ductal Adenocarcinoma
Colorectal Cancer
Gastrointestinal Cancer

Interventions: Drug: RMC-6236
Drug: mFOLFOX6 regimen
Drug: gemcitabine
Drug: bevacizumab
Drug: cetuximab
Drug: nab-paclitaxel
Drug: mFOLFIRINOX regimen
Drug: RMC-9805

First Posted Date: 2024-06-06

Last Posted Date: 2025-04-17

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 1130

Registration Number: NCT06445062

Locations: 🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
UCLA Hematology/Oncology- Santa Monica, Los Angeles, California, United States

and more 19 locations

Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
RAS G12D-mutated NSCLC

Interventions: Drug: RMC-6291
Drug: RMC-6236
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: RMC-9805

First Posted Date: 2023-12-08

Last Posted Date: 2025-05-08

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 484

Registration Number: NCT06162221

Locations: 🇮🇹
Ospedale Santa Maria Delle Croci, Ravenna, Italy
🇮🇹
IRCCS Instituto Nazionale tumori Ragina Elena, Rome, Italy
🇮🇹
Fondazione Policlinico Universitario A Gemelli-Rome, Rome, Italy

and more 56 locations

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors

Phase 1

Recruiting

Conditions: Colorectal Cancer
Pancreatic Ductal Adenocarcinoma
Non-Small Cell Lung Cancer (NSCLC)

Interventions: Drug: Assigned interventions

First Posted Date: 2023-11-13

Last Posted Date: 2025-03-27

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 210

Registration Number: NCT06128551

Locations: 🇮🇹
Niguarda Cancer Center, Milano, Italy
🇺🇸
City of Hope, Duarte, California, United States
🇺🇸
UC IRVINE Health, Orange, California, United States

and more 50 locations

Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Advanced Solid Tumors

Interventions: Drug: RMC-9805
Drug: RMC-6236

First Posted Date: 2023-09-15

Last Posted Date: 2025-04-03

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 444

Registration Number: NCT06040541

Locations: 🇺🇸
University of California, Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Smilow Cancer Hospital (Yale University), New Haven, Connecticut, United States
🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States

and more 14 locations

Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced Solid Tumor
Non-Small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Pancreatic Ductal Adenocarcinoma

Interventions: Drug: RMC-6291

First Posted Date: 2022-07-18

Last Posted Date: 2024-11-07

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 222

Registration Number: NCT05462717

Locations: 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
🇺🇸
University of Miami School of Medicine Sylvester Comprehensive Cancer Center, Miami, Florida, United States

and more 61 locations

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Phase 1

Recruiting

Conditions: Pancreatic Ductal Adenocarcinoma (PDAC)
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Advanced Solid Tumors

Interventions: Drug: RMC-6236

First Posted Date: 2022-05-18

Last Posted Date: 2024-11-14

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 614

Registration Number: NCT05379985

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
UC Irvine/Chao Family Comprehensive Cancer Center, Orange, California, United States
🇺🇸
UCLA, Santa Monica, California, United States

and more 13 locations

Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies

Phase 2

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: RMC-4630
Drug: Sotorasib

First Posted Date: 2021-09-23

Last Posted Date: 2025-04-24

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 47

Registration Number: NCT05054725

Locations: 🇺🇸
Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸
BRCR Medical Center Inc., Plantation, Florida, United States
🇺🇸
Hematology Oncology Clinic, Baton Rouge, Louisiana, United States

and more 56 locations

Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: RMC-5552

First Posted Date: 2021-03-01

Last Posted Date: 2025-04-15

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 58

Registration Number: NCT04774952

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Sarah Cannon Research Institute - Tennessee Oncology, PLLC, Nashville, Tennessee, United States
🇺🇸
UC Irvine - Chao Family Comprehensive Cancer Center, Irvine, California, United States

and more 5 locations

Home Terms & Conditions Privacy Policy